• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Ahmanson Translational Theranostics Division

UCLA Ahmanson Translational Theranostics Division

UCLA Ahmanson Translational Theranostics Division
  • Nuclear Medicine COVID-19 information
  • About Us
    • Directory
    • Locations and Directions
    • UCLA Pharmacology
    • Ahmanson Translational Imaging Division
  • Imaging Services
    • Cardiac Perfusion Scan (Nuclear Medicine and PET/CT)
    • Nuclear Medicine
    • PET and PET/CT
  • Patient Information
    • What Is Nuclear Medicine
    • FAQ
    • UCLA Neuroendocrine Tumor (NET) Program
    • Peptide Receptor Radionuclide (Lutathera) Therapy
  • Physician Information
    • Attending Schedule
    • Image Consultation
    • Insurance and Referral Codes
    • Clinical Instrumentation
  • Clinical Updates
  • Research
  • Education
    • Residency
    • PET Training
    • Nuclear Medicine Resident Manual
  • Contact Us
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Ahmanson Translational Theranostics Division

Patient Information

Patient Information

Patient Information

  • What Is Nuclear Medicine
  • FAQ
  • UCLA Neuroendocrine Tumor (NET) Program
  • Peptide Receptor Radionuclide (Lutathera) Therapy
  • What Is Nuclear Medicine
  • FAQ
  • UCLA Neuroendocrine Tumor (NET) Program
  • Peptide Receptor Radionuclide (Lutathera) Therapy
  1. Home
  2. Patient Information
  3. Peptide Receptor Radionuclide (Lutathera) Therapy

Peptide Receptor Radionuclide (Lutathera) Therapy

Share this

What is Lutathera?

Lutathera (177Lutetium 177-DOTATATE) is a recently FDA approved treatment option for metastatic neuroendocrine tumors of the stomach, gut or pancreas (GEP-NETs, sometimes also referred to as carcinoid tumors). Lutathera is the first type of Peptide Receptor Radionuclide Therapy (PRRT) approved by the U.S. Food and Drug Administration (FDA).  Because UCLA treated the largest number of patients in the US with Lutathera as part of an expanded access clinical trial prior to FDA approval, UCLA clinicians already have significant experience with this therapy. Patients receiving Lutathera treatments have seen a demonstrated reduction in the risk of disease progression, with results similar to the trials that led to FDA approval of Lutathera.

What is PRRT?

Lutathera is a radiolabeled somatostatin analog, a cell-targeting protein (or peptide) called octreotide combined with a radionuclide (177Lutetium), creating a special type of radiopharmaceutical called a radiopeptide. When injected into the patient’s bloodstream, this radiopeptide travels binds to neuroendocrine tumor cells, delivering a targeted dose of therapeutic radiation to the tumor cells.

World Class Care

Our clinicians and faculty consist of renowned experts in the diagnosis and treatment of neuroendocrine tumors. Actively involved in research and clinical trials, UCLA is one of the few expanded access Investigational New Drug trial sites for PRRT, making UCLA a true center of excellence. Our multidisciplinary team of clinicians include nuclear medicine physicians, oncologists, endocrinologists, gastroenterologists, surgeons and interventional radiologists.

The PRRT team is dedicated to providing the best possible care for our patients each and every time. Our patients are at the center of everything that we do.

For more information, please call the number below and let our staff know that you are calling about the Lutathera therapy.  You will then be directed to the most appropriate staff to help you with your inquiry:

Patients & Physicians

(310) 794-1005

For PRRT information please call Thaiza Adams at (310) 794-7741.

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth